Author:
Masuda N.,Toi M.,Yamamoto N.,Iwata H.,Kuroi K.,Bando H.,Ohtani S.,Takano T.,Inoue K.,Yanagita Y.,Kasai H.,Morita S.,Sakurai T.,Ohno S.
Funder
Japan Breast Cancer Research Group
GlaxoSmithKline
Kyoto University
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Radiology Nuclear Medicine and imaging,Oncology,General Medicine
Reference17 articles.
1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.
2. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Nancy ED, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–72.
4. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375:377–84.
5. Loibl S, von Minckwitz G, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. pCR as a surrogate in HER2-positive patients treated with trastuzumab. Cancer Res. 2011;71(S24):64s (abstr).
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献